2017.HSA.doxorubicin.AC.vs.ADTIC

多柔比星-环磷酰胺与多柔比星-达卡巴肼辅助治疗犬血管肉瘤的比较

Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma

https://doi.org/10.1111/vco.12139

摘要

犬血管肉瘤 （HSA） 是一种血管内皮起源的肿瘤，具有侵袭性生物学行为，在诊断后 12 个月内存活的狗不到 10%。首选的治疗包括手术，然后以阿霉素为基础的辅助化疗。我们前瞻性地比较了阿霉素和达卡巴嗪（ADTIC）辅助治疗与传统的多柔比星和环磷酰胺（AC）治疗，旨在确定安全性并评估该方案是否能延长生存期和转移时间（TTM）。招募了 27 只狗;分期检查后，18 例接受 AC 治疗，9 例接受 ADTIC 治疗。与接受AC治疗的狗相比，接受ADTIC治疗的狗的中位TTM和生存时间更长（分别为>550天和112天，P=0.021和>550天和142天，P=0.011）。两种方案的耐受性都很好，不需要减少剂量或增加治疗间隔。由多柔比星和达卡巴嗪联合组成的方案在患有 HSA 的狗中是安全的，并延长了 TTM 和生存时间。

Canine hemangiosarcoma (HSA) is a neoplasm of vascular endothelial origin that has an aggressive biological behaviour, with less than 10% of dogs alive at 12-months postdiagnosis. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Twenty-seven dogs were enrolled; following staging work-up, 18 were treated with AC and 9 with ADTIC. Median TTM and survival time were longer for dogs treated with ADTIC compared with those receiving AC (>550 versus 112 days, P = 0.021 and >550 versus 142 days, P = 0.011, respectively). Both protocols were well tolerated, without need for dose reduction or increased interval between treatments. A protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with HSA and prolongs TTM and survival time.